Suzhou Zelgen Biopharmaceuticals (688266) Stock Overview
Engages in the research, development, manufacture, sale, and distribution of medicines in the People's Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
688266 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥101.33 |
| 52 Week High | CN¥134.17 |
| 52 Week Low | CN¥58.00 |
| Beta | 0.20 |
| 1 Month Change | 0.65% |
| 3 Month Change | -3.95% |
| 1 Year Change | 62.81% |
| 3 Year Change | 148.36% |
| 5 Year Change | 51.33% |
| Change since IPO | 35.85% |
Recent News & Updates
Recent updates
Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHSE:688266) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable
Mar 03
Is Suzhou Zelgen BiopharmaceuticalsLtd (SHSE:688266) Using Debt Sensibly?
Jan 23Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) Earnings Haven't Escaped The Attention Of Investors
Nov 27Some Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHSE:688266) Analysts Just Made A Major Cut To Next Year's Estimates
Sep 11What Does The Future Hold For Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHSE:688266)? These Analysts Have Been Cutting Their Estimates
May 08Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) Shares Climb 28% But Its Business Is Yet to Catch Up
Mar 06Shareholder Returns
| 688266 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -7.4% | -1.2% | -0.3% |
| 1Y | 62.8% | 2.2% | 18.0% |
Return vs Industry: 688266 exceeded the CN Biotechs industry which returned 1.3% over the past year.
Return vs Market: 688266 exceeded the CN Market which returned 17.4% over the past year.
Price Volatility
| 688266 volatility | |
|---|---|
| 688266 Average Weekly Movement | 9.1% |
| Biotechs Industry Average Movement | 4.2% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in CN Market | 9.1% |
| 10% least volatile stocks in CN Market | 3.0% |
Stable Share Price: 688266's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 688266's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 910 | Zelin Sheng | www.zelgen.com |
Suzhou Zelgen Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, and distribution of medicines in the People's Republic of China. The company offers donafenib tablets for hepatocellular carcinoma and iodine-refractory differentiated thyroid cancer; recombinant human thrombin for hemostasis; and jacktinib tablets for intermediate and high-risk myelofibrosis. It also develops drug candidates in the NDA, Phase III, or registration clinical trial stages, such as gecacitinib hydrochloride tablets for severe alopecia areata, moderate to severe atopic dermatitis, ankylosing spondylitis, ruxolitinib-intolerant and relapsed/refractory myelofibrosis, moderate to severe plaque psoriasiste, idiopathic pulmonary fibrosis, severe alopecia areata, nonsegmental vitiligo, and myelofibrosis; and recombinant human thyroid-stimulating hormone for injection.
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Fundamentals Summary
| 688266 fundamental statistics | |
|---|---|
| Market cap | CN¥26.82b |
| Earnings (TTM) | -CN¥133.34m |
| Revenue (TTM) | CN¥742.28m |
Is 688266 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688266 income statement (TTM) | |
|---|---|
| Revenue | CN¥742.28m |
| Cost of Revenue | CN¥67.65m |
| Gross Profit | CN¥674.63m |
| Other Expenses | CN¥807.98m |
| Earnings | -CN¥133.34m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.50 |
| Gross Margin | 90.89% |
| Net Profit Margin | -17.96% |
| Debt/Equity Ratio | 97.1% |
How did 688266 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/19 08:48 |
| End of Day Share Price | 2025/12/19 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Suzhou Zelgen Biopharmaceuticals Co., Ltd. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jin Zhang | China International Capital Corporation Limited |
| Ziyu He | China International Capital Corporation Limited |
| Zhu Chen | Citic Securities Co., Ltd. |